Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 11 pp 10506—10516
Modification of graphene oxide by angiopep-2 enhances anti-glioma efficiency of the nanoscaled delivery system for doxorubicin
Figure 5. Angiopep-2 polypeptide-modified and doxorubicin-loaded graphene oxide (ANG-Dox-GO) inhibits metastasis in U87 MG cells. (A) The wound healing rate of U87 MG cells treated with PBS (control), GO, Dox (30 μg/mL), Dox-GO (containing 30 μg/mL of Dox), and ANG-Dox-GO (containing 30 μg/mL of Dox), respectively, at 0, 10, 12 h and 15 h by wound healing assay. (B) Cell migration and migration rates in U87 MG cells treated with PBS (control), GO, Dox (30 μg/mL), Dox-GO (containing 30 μg/mL of Dox), and ANG-Dox-GO (containing 30 μg/mL of Dox), respectively, by Transwell assay. *P < 0.05 vs control cells; #P < 0.05 vs Dox; &P < 0.05 vs. Dox-GO.